I
IMAGENEBIO, INC.
NASDAQ: IMA (ImageneBio, Inc.)
Kemas kini terakhir: 6 minit lalu4.10
0.00 (0.00%)
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | ImageneBio, Inc. | Bercampur | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.7 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| Persekitaran Makro | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | 0.58 |
|
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bvf Inc/Il | 30 Jun 2026 | 1,110,002 |
| Blue Owl Capital Holdings Lp | 30 Jun 2026 | 917,692 |
| Omega Fund Management, Llc | 30 Jun 2026 | 455,361 |
| Trails Edge Capital Partners, Lp | 30 Jun 2026 | 282,004 |
| Monashee Investment Management Llc | 30 Jun 2026 | 192,344 |
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |